Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies
Frank R. Brennan(AstraZeneca (United Kingdom)), David P. Humphreys(UCB Pharma (Belgium)), Joseph Ryan Polli(Novartis (China)), Patricia C. Ryan(Altimmune (United States)), Tilman Schlothauer(Roche (Switzerland)), Shirley J. Peters(UCB Pharma (Belgium)), Jan Terje Andersen(Oslo University Hospital), David Wensel(ViiV Healthcare (Spain)), Melissa Ramones(Novartis (China)), Prathap Nagaraja Shastri(Springhouse), Xiaoting Wang(Amgen (United States)), Masaki Honda(Aichi Gakuin University), Shermaine Mitchell-Ryan(Health and Environmental Sciences Institute), Changhua Ji(Yale University), Babette Wolf(Novartis (Switzerland)), Michael Doyle(Bristol-Myers Squibb (Germany)), Bianca Balbino(Argenx (Belgium)), Brian W. Soper(Jackson Laboratory), Adriano Flora(Jackson Laboratory), Jean G. Sathish(Pfizer (United States)), Derrick R. Witcher(Eli Lilly (United States)), Curtis C. Maier(GlaxoSmithKline (United Kingdom)), Eric Stefanich, Birgit Fogal(Boehringer Ingelheim (India)), Nidhi Sharda(Bristol-Myers Squibb (Germany)), Mary Struthers(Bristol-Myers Squibb (Germany)), Karen Price(Purchase College), T. Scott Manetz(AstraZeneca (Brazil)), Lindsey Dzielak(Boehringer Ingelheim (India)), Maximilian Brinkhaus(Sanquin)
Cited by 30
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
|Science|2020|415
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
|Protein Engineering Design and Selection|2016|409
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
|Science Translational Medicine|2017|361
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
|Frontiers in Immunology|2015|297